Mainline Biosciences, Inc.
1 clinical trials · Sponsor
◉ Watch Mainline Biosciences, Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer (NCT05465590) | Mainline Biosciences, Inc. | 2022-12-01 |
Track Mainline Biosciences, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.